Biotechnology company Pluri Inc. has been granted a new U.S. patent for a novel method for expansion of immune cells using proprietary technology.

How It Works

Pluri’s proprietary 3D cell expansion technology mimics the natural lymph node-like environment that immune cells have within the human body. The tightly controlled and fully automated bioreactor system provides cells with the conditions they need to expand, enabling efficient expansion of immune cells at scale and quality.
 
This approach ensures that the produced immune cells retain their integrity, functionality, and therapeutic efficacy, thus offering a promising solution to meet the escalating demand for advanced cell-based therapies for immune disorders and neurodegenerative diseases.
 
Pluri’s patented technology addresses the critical challenges faced by current allogeneic cell therapies, such as limited donor cell availability and scalability issues, and could potentially open doors to vast opportunities for therapeutic advancement and commercial success.
 
“We believe that our continued investment in technology, paired with two decades of expertise, enable us to develop the next generation of medical treatments,” said Yaky Yanay, CEO and President of Pluri. “Pluri’s patented technology represents a significant leap forward in the field of immune cell expansion, addressing the growing global demand for advanced cell-based therapies. By harnessing the power of our proprietary technology, we are not only advancing the possibilities of allogeneic cell therapy, we are also reaffirming our commitment to improving patient outcomes worldwide.”

More Pluri News

Earlier this year, Pluri Inc. launched a new business division offering cell therapy manufacturing services as a contract development and manufacturing organization (CDMO): PluriCDMO.